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Introduction:Clinical research in non–small-cell lung cancer 
(NSCLC) is a rapidly evolving field. In an effort to identify the cur-
rent trends in lung cancer clinical research, we reviewed ongoing 
clinical trials in NSCLC listed in the ClinicalTrials.gov registry in 
2012, and we also compared this data to a similar survey conducted 
by us in 2009.
Methods:The Web site’s advanced search function was used to 
search for the term “non-small cell lung cancer.” The search was 
further refined by using the following options from the search page 
drop-down menu, “open studies” and “interventional.” Studies with 
non-NSCLC tumor histologies and pediatric studies were excluded.
Results:Of the 477 trials included in the analysis, 105 (22.0%) were 
phase I, 223 phase II (46.8%), and 63 phase III trials (13.2%). When 
compared with data from 2009, university-sponsored trials decreased 
in number (45.4%–34.2%; p < 0.001) whereas industry-sponsored tri-
als remained almost the same. There was a significant increase in trials 
conducted exclusively outside of the United States (35.9%–48.8%; p 
= 0.001). The number of studies with locations in China (61, 12.8%) 
was second only to that in the United States (244, 51.2%). Studies 
reporting biomarker analysis increased significantly from 37.5% to 
49.1% in 2012 (p < 0.001). Biomarker-based patient selection also 
increased significantly from 7.9% to 25.8% (p < 0.001). Targeted 
therapies were evaluated in 70.6% of phase I/II and II trials, and the 
most common class of targeted agent studied was epidermal growth 
factor receptor tyrosine kinase inhibitors (38.0%). Prespecified 
accrual times were observed to increase when compared with data 
reported in 2009, especially among industry-sponsored studies.
Conclusions:Our survey identified major changes in lung cancer clin-
ical research since 2009. Almost half of all studies registered at the 
ClinicalTrials.gov Web site are being conducted outside the United 
States, and several novel molecularly targeted agents are being evalu-
ated in the treatment of patients with NSCLC. More importantly, we 
identified a threefold increase in the number of studies that perform 
biomarker testing to determine patient selection over the last 3 years.
Key Words: Non–small-cell lung cancer, ClinicalTrials.gov, Lung 
cancer, Ongoing studies.
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Lung cancer is the leading cause of cancer related death in both men and women.1 In 2012, it was estimated that 
there would be 226,160 new cases of lung cancer and 160,340 
related deaths in the United States. Despite some major 
advances in our understanding of cancer biology and the 
development of molecularly targeted drugs, there has been 
only an incremental improvement for patients with lung can-
cer. Further progress depends upon clinical trials that evaluate 
new diagnostic and treatment modalities for patients with lung 
cancer. Clinical trials evaluating anticancer drugs require sig-
nificant resources, and the vast majority of them do not meet 
their stated endpoints.3,4 We need a better understanding of 
the composition and characteristics of these trials to improve 
trial design, identify neglected areas of research, and promote 
diverse lung cancer research.
Three years ago, we surveyed5 ongoing therapeutic 
clinical trials for patients with non–small-cell lung cancer 
(NSCLC), registered with ClinicalTrials.gov Web site and 
the goal of that study was to shed light on trends in clinical 
trials research, the impact of new developments, such as the 
use of targeted therapies for the treatment of lung cancer, and 
the development of novel clinical trial designs to improve the 
efficiency of clinical trial research. For the first time, the study 
described ongoing clinical trials evaluating treatments for lung 
cancer and also identified that only 8% of the trials used a 
biomarker-based patient selection method. Given the need for 
better and more efficient clinical trials, we planned on repeating 
the survey every few years to identify new developments and 
to keep the information current to guide future trial design.
Copyright © 2013 by the International Association for the Study of Lung 
Cancer
ISSN: 1556-0864/13/0807-0860
Review of Ongoing Clinical Trials in Non–Small-Cell  
Lung Cancer
A Status Report for 2012 from the ClinicalTrials.gov Web Site
Janakiraman Subramanian, MD, MPH,* Thomas Regenbogen, MB BCh BAO,† Gayathri Nagaraj, MD,‡ 
Alex Lane, BS,§ Siddhartha Devarakonda, MD,║ Gongfu Zhou, PhD,¶ and Ramaswamy Govindan, MD§# 
*Department of Medicine, University of Tennessee Medical Center, 
Knoxville, Tennessee; †Department of Medicine, Washington University 
School of Medicine, St. Louis, Missouri; ‡Department of Medicine, 
Division of Hematology and Oncology, Loma Linda University,Loma 
Linda, California; §Department of Medicine, Division of Oncology, 
Washington University School of Medicine in St. Louis, Missouri; 
║Department of Medicine, St. Lukes Hospital, St. Louis, Missouri; 
¶Division of Biostatistics, Washington University School of Medicine in 
St. Louis, Missouri; and #Alvin J. Siteman Cancer Center.
Disclosure: The authors declare no conflict of interest.
Address for correspondence: Ramaswamy Govindan, MD, Division of 
Medical Oncology, Washington University School of Medicine, 660 S. 
Euclid, Box 8056, St. Louis, MO. E-mail: rgovinda@dom.wustl.edu
STATE OF THE ART: CONCISE REvIEW
861Copyright © 2013 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology®  •  Volume 8, Number 7, July 2013 Review of Clinical Trials in NSCLC
The ClinicalTrials.gov Web site was established by 
the Department of Health and Human Services based on 
the 1997 Food and Drug Administration Modernization Act 
and is maintained by the National Library of Medicine at 
the National Institute of Health.6 It is a publicly accessible 
resource, where all studies in the United States are required to 
register under federal penalty.7 The International Committee 
of Medical Journal Editors (ICMJE) requires that all clinical 
trials be enrolled in a freely accessible registry before patient 
enrollment.8 The ClinicalTrials.gov Web site provides a vehi-
cle that allows international organizations to comply with this 
requirement. This study is a follow-up on our 2009 survey and 
identifies the progress made in clinical trial design and imple-
mentation in the last 3 years.
MATERIALS AND METHODS
The data for this study were collected from the 
ClinicalTrials.gov, which is an open-access Web site. The 
advanced search option was used with the search term, “non-
small cell lung cancer.” The search was refined by selecting 
“open studies” for recruitment status, “interventional studies” 
for study type and selection to adult (18–65 years) and senior 
(66 years and above) age groups. We used the same search 
criteria as used in our previous study published in 2010. Trials 
were excluded from analysis if they did not involve patients 
diagnosed with NSCLC or did not list medical therapy as an 
intervention. Our search was executed on March 8, 2012, and 
the results were saved to a database file. We extracted the fol-
lowing information: (1) clinical trial phase; (2) recruitment 
status; (3) staging per American Joint Committee on Cancer 
guidelines; (4) study design including randomization, control 
group, and number of arms; (5) site location; (6) sponsor; (7) 
subject accrual time; (8) histology; (9) treatment setting and 
modality; (10) biomarker analysis; and (11) biomarkers. Study 
data accuracy was ensured by independent verification of the 
entire data by three investigators. Statistical analysis was per-
formed to compare data collected in 2012, with previously 
published data from 2009. Contingency tables were created 
for comparison and Fisher’s exact test was used to determine 
whether significant difference existed between these two 
groups. Data groups analyzed by this method included: (1) 
study characteristics, including phase, sponsor, recruitment 
status, study location, randomization, and number of treatment 
arms, (2) biomarker analysis, including whether biomarker 
testing was used for patient selection or as inclusion criteria 
treatment regimen among studies with biomarker analysis, and 
type of trials analyzing biomarkers. Statistical analysis was not 
used to compare the type of study outcomes because many 
trials listed multiple primary outcomes or did not clearly list 
the primary endpoint. Similarly, we did not calculate statistical 
significance for differences in the distribution of drug types 
because the earlier 2009 survey reported only percentages, 
and also, we did not do a statistical comparison of projected 
accrual time because some studies did not report this data.
RESULTS
Our search identified a total of 704 trials, of which 227 
were excluded from analysis because they included patients 
with tumor histologies other than NSCLC or they did not 
include medical therapy for patients with lung cancer. Of the 
477 trials selected for analysis, 440 (92.2%) were actively 
recruiting, 31 (6.5%) were not yet recruiting, and six had 
either completed recruitment, or had an unlisted recruitment 
status but were present in the search result. These six studies 
were included in the final analysis based on an intention-to-
treat principle.
Phase II studies (223, 46.8%) were the most common 
study type, followed by phase I (105, 22.0%), and phase III 
(63, 13.2%). The distribution of studies was similar to what 
we had reported in our 2009 survey (p = 0.59; Table 1). In 
2012, fewer studies listed universities as the primary spon-
sor compared with data from 2009 (45.4% versus 34.2%; p 
< 0.001). Phase I/II and II trials were sponsored more often 
by universities (36.6%) than industry sponsors (27.2%) and 
other organizations (22.6%), whereas more number of phase 
III trials were sponsored by industry (46.0%) compared 
with 11.1% sponsored by universities and 17.4% by other 
organizations.
More than half (55.8%) of all clinical trials had multiple 
study locations, which was similar (56.8%) to that reported 
in the 2009 survey (p = 0.8). In 2012, the United States was 
TABLE 1.  Characteristics of All Clinical Trials Included in 
Analysis
2009 (%) 2012 (%) p
N 493 477
Type of clinical trial 0.59
 Phase I 92 (18.7) 105 (22.0)
 Phase I/II 61 (12.4) 56 (11.7)
 Phase II 240 (48.7) 223 (46.8)
  Phase II/III 3 (0.6) 7 (1.5)
 Phase III 77 (15.6) 63 (13.2)
 Phase Iv 8 (1.6) 9 (1.9)
 Unspecified 12 (2.4) 8 (1.7)
Pilot studies Not reported 6 (1.2)
Primary sponsor <0.001
 Industry 166 (33.7) 158 (33.1)
 University 224 (45.4) 163 (34.2)
 Cooperative group 43 (8.7) 46 (9.6)
 National Cancer Institute 18 (3.7) 21(4.4)
 Others 42 (8.5) 89 (18.7)
Recruitment status 0.079
 Actively recruiting 472 (95.7) 440 (92.2)
 Not yet open for recruitment 19 (3.9) 31 (6.5)
 Closed to recruitment 2 (0.4) 4 (0.8)
Number of study locations 0.08
 Single-study location 213 (43.2) 211 (44.2)
 Multiple-study locations 280 (56.8) 266 (55.8)
Location <0.001
 United States only 253 (51.3) 189 (39.6)
 International only 177 (35.9) 233 (48.8)
 Located in United States  
 and elsewhere
63 (12.8) 55 (11.5)
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the most common study location (244, 51.1%), followed by 
the People’s Republic of China (61, 12.8%), the Republic of 
Korea (56, 11.7%), and then the European countries, including 
France (46, 9.6%), Germany (44, 9.2%), Italy (41, 8.6%), and 
the United Kingdom (34, 7.1%). Another notable finding in our 
2012 data was that when compared with 2009, fewer studies 
were listed as taking place solely in the United States (39.6% 
versus 51.3%; p < 0.001), whereas there was an increase in stud-
ies that listed only locations outside the United States (48.8% 
versus 35.9%; p < 0.001). The percentage of trials occurring in 
both international locations and in United States was 12.8% in 
2009 and 11.5% in 2012. International trials without locations 
in the United States accounted for a significant proportion of 
the phase III trials (40, 63.5%) and approximately half of phase 
I/II and phase II trials (145, 52.0%). Of the 40 phase III tri-
als with locations exclusively outside of the United States, 17 
studies (42.5%) had locations in Europe, 18 in Asia, and four 
additional studies (1.0%) listed locations in both regions.
Among phase I/II and II trials, 59.9% were 
nonrandomized, the majority were open label (92.8%), and had 
single-arm design (58.1%; Table 2) In contrast, phase III trials 
were all randomized, more than half were open-label studies 
(66.7%) and most of them (93.7%) had at least two treatment 
arms. There did not seem to be any significant change in the 
distribution of the most common outcome measures between 
the two surveys. In phase II trials the most frequent primary 
outcome measure was progression-free survival, followed by 
response rate, and then overall survival (Table 3). Similarly, 
in phase III trials the most common outcomes continued to 
be overall survival followed by progression-free survival. 
The majority of phases I/II, II, II/III, and III studies evaluated 
treatment in patients with advanced stage NSCLC (267, 
76.5%). Overall, these findings were not significantly different 
from the 2009 data (p = 0.6; Table 4)
Most studies included some form of targeted therapeutic 
agent in their treatment arms (Table 5). Many studies involved 
a combination of standard-of-care treatment with molecularly 
targeted agents. In phase I/II, II, II/III, and III trials, combined 
targeted and cytotoxic drugs accounted for 36.1% of all 
trials compared with 30.1% in 2009, targeted agents alone 
or in combination with radiation or alternative therapies 
accounted for 32.1% as compared with 29.1% in 2009, and 
finally cytotoxic drugs alone or in combination with radiation 
or alternative therapies accounted for 30.1% compared with 
26.8% in the previous study. In clinical trials examining 
targeted drugs, 38.0% used first-generation epidermal growth 
factor receptor tyrosine kinase inhibitors (EGFR TKI) 
(Table 6) This was followed by multireceptor TKI (which 
includes vascular endothelial growth factor receptor TKIs), 
EGFR antibodies, and second-generation EGFR TKI.
There were significant differences in the number of 
studies with biomarker analysis between 2009 and 2012 
(Table 7). The total number of studies, including biomarker 
analysis, increased from 37.5% to 49.1% in 2012 (p < 0.001). 
In 2012, almost all (97.0%) studies analyzing biomarkers 
specified the biomarker being tested, as opposed to only 
78.4% of the trials specifying the biomarker (p < 0.001) in 
TABLE 2.  Selected Characteristics of Phase II and III Trial
Study Design
Number of  
Phase I/II  
and II Trials 
(%) N = 279
Number of 
Phase II/III 
Trials  
(%) N = 7
Number of 
Phase III  
Trials  
(%) N = 63
Randomization
 Randomized 111 (39.8) 7 (100) 63 (100)
 Nonrandomized 167 (59.9) 0 (0.0) 0 (0.0)
 Open label 259 (92.8) 4 (57.1) 42 (66.7)
 Single blinded 2 (0.7) 0 (0.0) 1 (1.6)
 Double blinded 18 (6.5) 3 (42.9) 20 (31.7)
Number of treatment arms
 1 162 (58.1) 0 (0.0) 0 (0.0)
 2 102 (36.5) 7 (100) 59 (93.7)
 ≥3 15 (5.4) 0 (0.0) 4 (6.3)
Type of control arm
 Placebo onlya 0 (0.0) 2 (28.6) 3 (4.8)
 Standard care/active  
 control
94 (33.7) 5 (71.4) 49 (77.8)
 Uncontrolled 185 (66.3) 0 (0.0) 11 (17.4)
a  Placebo only and excludes studies with placebo in conjunction with best 
standard of care/active control.
TABLE 3.  Primary Outcomes of Phase II and III Trials
Outcome
Phase IIa Phase III
2009 2012b 2009  2012c
OSd 32 (10.6) 28 (10.0) 50 (64.9) 37 (58.7)
PFS 106 (35.2) 96 (34.4) 21 (27.3) 19 (30.2)
RR 111 (36.9) 87 (31.2) 1 (1.3) 2 (3.2)
DFS 1 (0.33) 3 (1.1) 1 (1.3) 2 (3.2)
Feasibility 10 (3.3) 10 (3.6) 1 (1.3) 0 (0.0)
a Includes phase I/II and II trials.
b Many studies listed up to 4 primary outcomes, thus the total sum will be different 
than total number of phase I/II and II trials analyzed.
c Three studies listed 2 primary outcomes.
d Includes OS, mean survival, survival, and time-specified survival.
OS, overall survival; PFS, progression-free survival; RR, response rate; DFS, 
disease-free survival.
TABLE 4.  Treatment Setting in Phase II and III Trialsa
Treatment Setting
Year and Number of Trials
p2009 (N = 381) 2012 (N = 349)
Adjuvant 22 (5.8) 15 (4.3) p = 0.6
Neoadjuvant 18 (4.7) 20 (5.7)
Neoadjuvant/adjuvant 7 (1.8) 4 (1.1)
Concurrent 38 (10.0) 43 (12.3)
Palliative total 294 (77.2) 267 (76.5)
First-line (palliative) 130 (34.1) 115 (33.0)
First- or second-line (palliative) 7 (1.8) 6 (1.7)
Second-line or more (palliative) 132 (34.7) 113 (32.4)
Any line (palliative) 11 (2.9) 7 (2.0)
Unspecified palliative line 14 (3.7) 26 (7.4)
a Includes phases I/II, II, II/III, and III.
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2009. When compared with clinical trials registered in 2009, 
which included biomarker analysis, the proportion of such 
studies with molecularly targeted therapy increased from 
42.7% to 47.9% in 2012 (p = 0.02). Importantly, there was 
a significant increase in the number of studies using bio-
markers to select patients, either for inclusion in the study, 
or directing them to specific treatment arms (7.9%–25.8%; p 
< 0.001). The most common biomarker was EGFR (62.6%) 
followed by KRAS (11.4%). ALK rearrangements were used 
for patient selection in six trials (4.9%). Among the 16 phase 
III trials with biomarker-directed patient selection, 10 trials 
(62.5%) used EGFR status. Similarly, in the 80 phase II trials 
with biomarker-directed patient selection, 54 trials (67.5%) 
included EGFR.
Studies that are registered on the ClinicalTrials.gov 
Web site also have to provide the time duration over which 
they plan to accrue all of their patients. Because the timeline 
for patient enrolment is significantly different between 
phase II and phase III trials, we analyzed them separately 
(Supplemental Tables 1 and 2, Supplemental Digital Content 
1, http://links.lww.com/JTO/A402). The prespecified accrual 
data were not reported for all studies. Of all phase II and III 
studies in 2012, 27 studies (9.4%) did not report their accrual 
time. Overall, clinical trials in 2012 had longer projected 
accrual times compared with those in 2009. Among phase II 
trials, the number of studies with projected accrual times less 
than a year dropped from 93 (38.8%) in 2009, to 19 (8.5%) in 
2012. Industry-sponsored studies had the greatest reduction 
in the number of phase II trials with less than 1 year projected 
accrual time (62.1%–8.0%) and a similar trend was seen in 
all sponsor groups. As a result, there was an increase in the 
proportion of phase II clinical trials with projected accrual 
times of 12 to 24 months and greater than 24 months in 2012 
(Supplemental Table 1, Supplemental Digital Content 1, 
http://links.lww.com/JTO/A402). This increase was primarily 
seen in industry-sponsored trials, with the proportion of 
studies with accrual time of 12 to 24 months increasing from 
21.2% in 2009 to 34.0% in 2012. A similar trend was seen 
for studies with greater than 24 months’ projected accrual 
time by the increase from 16.7% to 58.0%. Projected accrual 
time for phase III studies in 2012 had a similar trend with 
a significant decline in the proportion of trials with accrual 
times less than 12 months from 27.2% to 3.2%. Notably, there 
were 13 industry trials (39.4%) with accrual times less than 
12 months in 2009, and in 2012 there were no industry trials 
listing their projected accrual time as less than 12 months. In 
contrast to phase II trials, the 12- to 24-month accrual time 
also decreased for phase III trials. There were more studies in 
the greater-than-24-month time frame, and notably, industry 
trials with accrual times over 36 months increased from 
18.2% in 2009 to 62.1% in 2012.
DISCUSSION
Our follow-up survey of ongoing trials in NSCLC regis-
tered with ClinicalTrials.gov yielded several interesting find-
ings. The basic study characteristics have remained largely 
unchanged from our 2009 survey; the majority of the stud-
ies were multicenter phase II clinical trials. As expected, the 
TABLE 5.  Type of Medical Therapy Being Evaluated in 
Patients with NSCLC
Phase I  
(%) 
N = 105
Phase I/II, 
II (%) 
N = 279
Phase II/III 
(%) 
N = 7
Phase III 
(%) 
N = 63
Targeted therapy 70 (66.7) 197 (70.6) 5 (71.4) 36 (57.1)
Chemotherapy 48 (45.7) 175 (62.7) 5 (71.4) 51 (81.0)
Immunotherapy 20 (19.0) 13 (4.7) 2 (28.6) 6 (9.5)
Other 7 (6.7) 11 (3.9) 0 (0.0) 0 (0.0)
Total exceeds 100% of studies included in this analysis because of multiple 
modalities used in some studies.
TABLE 6.  Targeted Therapies Being Evaluated in Lung Cancer
Targeted Therapy Number of Studiesa (N = 308)(%)
EGFR TKI (first generation) 117 (38.0)
Multitargeted TKIb 37 (12.0)
EGFR antibodies 21 (6.8)
Second-generation EGFR inhibitorsc 20 (6.5)
HDAC inhibitor 20 (6.5)
MTOR inhibitor 14 (4.5)
PI3K inhibitor 11 (3.6)
CMET inhibitor 11 (3.6)
Hsp 90 inhibitors 7 (2.3)
Other 49 (15.9)
a Phase I, I/II, II, II/III, and III with targeted agents.
b Multitargeted TKI includes vEGF TKI.
c Second-generation EGFR inhibitors include: Her2/EGFR, PanHER inhibitor, HER3 Ab.
TABLE 7.  Characteristics of Clinical trials with Biomarker 
Analysis 
2009 N (%) 2012 N (%) p
Studies with biomarker analysis 185 (37.5) 234 (49.1) <0.001
Biomarker(s) specified <0.001
 Yes 145 (78.4) 226 (96.6)
 No 40 (21.6) 8 (3.4)
Biomarker-based patient selection 39 (7.9) 123 (25.8) <0.001
Biomarker used in patient selection 0.08a
 EGFR-based selection 17 (43.6) 77 (62.6)
 KRAS-based selection 5 (12.8) 14 (11.4)
 BRAF-based selectiona Unreported 8 (6.5)
Treatment regimen in studies with  
 biomarker analysisb
0.02
 Targeted therapy 79 (42.7) 112 (47.9)
 Chemotherapy with targeted agent 46 (24.9) 67 (28.6)
 Chemotherapy 24 (13.0) 37 (15.8)
 Immune 23 (12.4) 24 (10.3)
 Alternative 2 (1.1) 0 (0.0)
 Others 11 (5.9) 11 (4.7)
a BRAF excluded from statistical analysis.
b Total exceeds 100% because of overlap in treatment modalities in 2012.
BRAF, v-raf murine sarcoma viral oncogene homolog B1.
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vast majority of trials were focused on treating patients with 
advanced stage disease.
We find that globalization has had a major impact on 
lung cancer clinical trials, with nearly half of all clinical 
trials (irrespective of the phase of the studies) now being 
conducted outside the United States, primarily in Asia, fol-
lowed closely by Europe. This is different from 2009 because 
only a third of the clinical trials at that time were conducted 
exclusively outside the United States. A new finding was that 
63.5% of phase III trials were located outside of the United 
States with a similar distribution between Europe and Asia. 
In fact, the number of clinical trials conducted outside the 
United States is likely to be even higher because interna-
tional trials are not required to register with ClinicalTrials.
gov, though, the ICMJE does require registration in a publicly 
accessible register.8 The smaller international registries tend 
to be regional, and in our preliminary research, we observed 
overlap between these registries and ClinicalTrials.gov, sug-
gesting that this is the preferred registry (data not shown).
Not surprisingly, industry sponsorship is significantly 
higher for phase III trials, given the expenses and the com-
plexities associated with conducting large studies..9 Despite 
the majority of phase II trials taking place in academic institu-
tions, they remain predominantly nonrandomized, open-label 
studies with single-arm design, consistent with the data from 
our earlier publication.5 Furthermore, response rate continues 
to be used frequently as a primary outcome, despite evidence 
that it may not be an optimal predictor for successful phase III 
outcomes.10,11
One of the key findings in this study was that the number 
of clinical trials with biomarker-based treatment selection for 
lung cancer has significantly increased over the last 3 years. 
In 2009, biomarkers received limited attention in lung can-
cer clinical trials, especially with regard to patient selection. 
Over the last few years, there has been ongoing discussion 
on the need for biomarker-based patient selection, particu-
larly for clinical trials involving molecularly targeted thera-
pies.12–14 This discussion seems to have had a definite impact, 
and the number of clinical trials with biomarker-based patient 
selection has tripled in 2012. However, there is still signifi-
cant room for improvement because nearly 80% of all clini-
cal trials include targeted therapies and this is very likely to 
increase. Most of the clinical trials involving molecularly tar-
geted drugs for lung cancer are focused on targeting EGFR. In 
comparison, only a few studies include testing for ALK rear-
rangement as inclusion criteria or to direct therapy. There are 
several new trials focusing on novel targets such as the Pi3K/
MTOR pathway, MET, and heat-shock proteins. Overall, the 
increasing trend to incorporate biomarker-based patient selec-
tion is a welcome development.
Achieving patient accrual targets is essential for suc-
cessful completion of any clinical trial.15 In the United 
States, only 3% to 14% of adults with cancer participate in 
clinical trials.16,17 In our study, we observed that the prespeci-
fied accrual times for both phase II and phase III trials have 
increased when compared with data from 2009. This increase 
has been uniform across the board for all study sponsors and 
especially, among industry-sponsored studies. The addition 
of biomarker-based patient selection, where only a smaller 
number of patients are potentially eligible for trial participa-
tion, might have led to a realistic projection of timelines.
There are several limitations to our study. The accuracy 
of the data relies on the study sponsor, and data entry is not 
uniform across studies, with some studies having a wealth of 
information and some others providing the bare minimum 
details. Because the registry is based in the United States, 
it is not a comprehensive database for all lung cancer trials. 
Many international trials and even some trials in the United 
States also may not have been registered on the Web site. The 
requirements by ICMJE that clinical trials should have been 
registered on the Web site before publication of the Food and 
Drug Administration Amendments Act of 2007, which has 
established penalties for failing to register, are powerful incen-
tives to ensure that the vast majority of clinical trials in the 
United States, and many other internationals trials as well, are 
registered on the ClinicalTrials.gov Web site. Human error in 
data collection is another potential source of inaccuracy. To 
avoid such inaccuracies, we implemented multiple layers of 
data verification, including an initial complete review of the 
entire data to ensure data accuracy. The strength of this study 
is our ability to compare the study data with data from 2009, 
and the comprehensive nature of ClinicalTrials.gov database, 
which, since 2009, requires sponsors to provide even more 
detailed information regarding their studies.
Overall, our new survey shows that there has been some 
significant progress in the design and implementation of lung 
cancer clinical trials, particularly in the use of biomarker-
based patient selection. Given the molecular heterogeneity of 
lung cancer and the narrow spectrum of activity with molecu-
larly targeted agents, rational drug development is critical to 
improve the outcomes of patients with lung cancer.
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